Table 1.
Patient Characteristics.
| Variable | Overall N = 26 | HER2− N = 20 | HER2+ N = 6 |
|---|---|---|---|
| Age, years, median (range) | 50 (31–74) | 51 (32–74) | 41 (31–72) |
| Race, n (%) | |||
| White | 15 (58%) | 14 (70%) | 1 (17%) |
| African-American | 5 (19%) | 5 (25%) | 0 (0%) |
| Asian | 5 (19%) | 1 (5%) | 4 (67%) |
| Other | 1 (4%) | 0 (0%) | 1 (17%) |
| ECOG status, n (%) | |||
| 0 | 11 (42%) | 10 (50%) | 1 (17%) |
| 1 | 12 (46%) | 8 (40%) | 4 (67%) |
| 2 | 3 (12%) | 2 (10%) | 1 (17%) |
| ER status, n (%) | |||
| ER-positive | 13 (50%) | 12 (60%) | 2 (33%) |
| ER-negative | 13 (50%) | 8 (40%) | 4 (67%) |
| Time from initial diagnosis to metastatic diagnosis, years, median (range) | 3.3 (0.0–16.3) | 3.5 (0.0–12.4) | 1.8 (0.1–16.3) |
| Time from metastatic diagnosis to study enrollment, years, median (range) | 2.0 (0.1–7.4) | 2.1 (0.1–7.4) | 1.4 (0.5–3.4) |
| Metastatic non-CNS sites at study entry, n (%) | |||
| Bone | 21 (81%) | 16 (80%) | 5 (83%) |
| Lymph node | 19 (73%) | 14 (70%) | 5 (83%) |
| Lung | 20 (77%) | 15 (75%) | 5 (83%) |
| Liver | 14 (54%) | 12 (60%) | 2 (33%) |
| 0–1 sites | 0 (0%) | 0 (0%) | 0 (0%) |
| 2–3 sites | 20 (76%) | 15 (75%) | 5 (83%) |
| 4+ sites | 6 (23%) | 5 (25%) | 1 (17%) |
| Number of prior chemotherapy regimens in metastatic setting, median (range)a | 2 (0–6) | 3 (0–6) | 1 (1–5) |
| 0 therapies, n (%) | 3 (12%) | 3 (16%) | 0 (0%) |
| 1 therapy, n (%) | 8 (32%) | 4 (21%) | 4 (67%) |
| 2 therapies, n (%) | 2 (8%) | 1 (5%) | 1 (16.5%) |
| 3 therapies, n (%) | 7 (28%) | 7 (37%) | 0 (0%) |
| 4+ therapies, n (%) | 5 (20%) | 4 (21%) | 1 (16.5%) |
| ALC at baseline (K/µl)a | |||
| <1.0 | 12 (48%) | 8 (42%) | 4 (67%) |
| ≥1.0 | 13 (52%) | 11 (58%) | 2 (33%) |
| Non-CNS disease at study start, n (%) | |||
| PD | 25 (96%) | 19 (95%) | 6 (100%) |
| SD | 1 (4%) | 1 (5%) | 0 (0%) |
| Brain RT received, n (%) | |||
| WBRT | 23 (88%) | 17 (85%) | 6 (100%) |
| SRS | 3 (12%) | 3 (15%) | 0 (0%) |
| No. of RT doses received, median (range) | 4 (1–11) | 4 (1–6) | 5 (2–11) |
ECOG Eastern Cooperative Oncology Group, HER human epidermal growth factor receptor, ER estrogen receptor, CNS central nervous system, ALC absolute lymphocyte counts, RT radiation therapy, WBRT whole brain radiation therapy, SRS stereotactic radiosurgery.
aOne patient not included because of consent withdrawal.